Sequential therapy comprising a 20(S)-camptothecian and a pyrimidine base analog

a technology of pyrimidine and sulfonamide, which is applied in the field of treating disease using a 20 (s)-camptothecin and a pyrimidine base analog, can solve the problems of high toxicity and low potency, study abandonment, and low utility of 5-fluorouracil

Inactive Publication Date: 2006-03-09
SUPERGEN
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The studies were later abandoned because of the high toxicity and low potency of 20(S) camptothecin Na+.
The utility of 5-fluorouracil has however been low due to toxic side effects, a common problem with anti-cancer agents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] The present invention relates to the sequential delivery of a 20(S)-camptothecin and a pyrimidine base analog where one therapeutic agent, most typically a 20(S)-camptothecin, is administered to a patient for a period of time during which the other therapeutic agent is not administered to the patient. Optionally, one therapeutic agent is administered to a patient when the other is not present in a pharmacologically active form in the patient's body. The period of time when only one of the therapeutic agents is administered or where only one of the therapeutic agents is present in a pharmacologically active form in the patient's body may be at least one, two, three, four, five or more days.

[0029] It is noted that sequential delivery optionally also includes periods of time where both therapeutic agents are administered to the patient and / or where both therapeutic agents are present in pharmacologically active forms in the patient's body.

[0030] By administering these differen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

Description

CROSS-REFERENCE [0001] This application is a continuation application of application Ser. No. 10 / 081,974, filed Feb. 21, 2002, which is incorporated herein by reference in its entirety and to which application we claim priority under 35 USC § 120:BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] This invention relates to a method for treating disease using a 20(S)-camptothecin and a pyrimidine base analog, and more specifically a method for treating disease using a 20(S)-camptothecin and pyrimidine base analog in a sequential therapy. [0004] 2. Description of Related Art [0005] A. 20(S)-Camptothecins [0006] 20(S)-camptothecin, a plant alkaloid, was found to have anticancer activity in the late 1950's. Wall, M. et al., Plant anti-tumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, J. Am. Chem. Soc. 88: 3888-3890, (1966); Monroe E. Wall et al., Camptothecin: Discovery to Clinic, 803...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7072A61K31/513A61K31/4745
CPCA61K31/4745A61K31/513A61K31/7072A61K2300/00
Inventor RUBINFELD, JOSEPHMETTINGER, KARL L.LYONS, JOHNROMEL, LAWRENCE A.
Owner SUPERGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap